Selected research
Industry Research
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Research Report 2026
Market perspective
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs include Allergan, Amneal Pharms, Astellas Pharmaceuticals, Bausch Health, Sebela Pharmaceuticals and Pharscin Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Company
Allergan
Amneal Pharms
Astellas Pharmaceuticals
Bausch Health
Sebela Pharmaceuticals
Pharscin Pharma
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
XIFAXAN
Lotronex
Viberzi
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application
Hospitals Pharmacy
Retail Pharmacy
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- XIFAXAN
- Lotronex
- Viberzi
- Other
Applications
- Hospitals Pharmacy
- Retail Pharmacy
- Other
Companies covered
- Allergan
- Amneal Pharms
- Astellas Pharmaceuticals
- Bausch Health
- Sebela Pharmaceuticals
- Pharscin Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (2021-2032)
- 2.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2021-2032)
- 2.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Average Price (2021-2032)
- 2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 XIFAXAN
- 2.3.3 Lotronex
- 2.3.4 Viberzi
- 2.3.5 Other
- 2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals Pharmacy
- 2.4.3 Retail Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs) of Manufacturers (2021-2026)
- 3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Type & Application
- 3.8 Global Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Established Date
- 3.9 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Allergan
- 4.1.1 Allergan Company Information
- 4.1.2 Allergan Business Overview
- 4.1.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 4.1.5 Allergan Recent Developments
- 4.2 Amneal Pharms
- 4.2.1 Amneal Pharms Company Information
- 4.2.2 Amneal Pharms Business Overview
- 4.2.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 4.2.5 Amneal Pharms Recent Developments
- 4.3 Astellas Pharmaceuticals
- 4.3.1 Astellas Pharmaceuticals Company Information
- 4.3.2 Astellas Pharmaceuticals Business Overview
- 4.3.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 4.3.5 Astellas Pharmaceuticals Recent Developments
- 4.4 Bausch Health
- 4.4.1 Bausch Health Company Information
- 4.4.2 Bausch Health Business Overview
- 4.4.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 4.4.5 Bausch Health Recent Developments
- 4.5 Sebela Pharmaceuticals
- 4.5.1 Sebela Pharmaceuticals Company Information
- 4.5.2 Sebela Pharmaceuticals Business Overview
- 4.5.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 4.5.5 Sebela Pharmaceuticals Recent Developments
- 4.6 Pharscin Pharma
- 4.6.1 Pharscin Pharma Company Information
- 4.6.2 Pharscin Pharma Business Overview
- 4.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 4.6.5 Pharscin Pharma Recent Developments
5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Scenario by Region
- 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021-2032
- 5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021-2026
- 5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2027-2032
- 5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2027-2032
- 5.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
- 5.4.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
- 5.4.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
- 5.5.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
- 5.7.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
- 5.7.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032)
- 6.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032) & (K Pcs)
- 6.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032)
- 7.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032) & (K Pcs)
- 7.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Analysis
- 8.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
- 8.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
- 8.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
9 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Analyzing Market Dynamics
- 9.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
- 9.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
- 9.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
- 9.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst